ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2027

Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome

Uzma Nakshbandi1, Martha S. van Ginkel1, Silvia Liefers2, Hendrika Bootsma2, Fred Spijkervet2, Arjan Vissink1, Bert van der Vegt1 and Frans Kroese2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

Meeting: ACR Convergence 2022

Keywords: B-Lymphocyte, Diagnostic criteria, Inflammation, Sjögren's syndrome, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren’s syndrome (pSS). This is reflected by the prominent role of a positive biopsy within the ACR-EULAR classification criteria, which is solely based on the focus score (FS). In pSS all salivary glands might be involved in the disease process. For this reason, both labial and parotid salivary gland biopsies can be used for diagnosis and evaluation. Although nearly all clinical centres obtain labial gland biopsies for classification and diagnosis of pSS, a parotid biopsy is also a safe and effective procedure. Furthermore, it has a comparable diagnostic potential in pSS, might be associated with less morbidity, and may even detect presence of subclinical MALT lymphomas. However, histopathological differences between both types of salivary glands should potentially be taken into account.

The aim of this study was to get histopathological insight in minor (labial) and major (parotid) salivary glands in pSS patients in comparison with non-SS sicca patients.

Methods: Both labial and parotid salivary gland biopsies were obtained from 99 patients. According to the expert opinion of three experienced rheumatologists, 36 patients were classified as pSS patients and 63 as non-SS sicca patients. Salivary gland biopsies were formalin fixed, paraffine embedded and serially sectioned at 3-4µm. Sections were stained with H&E and for CD3, CD20, CD45, hmwCK, CD21, Bcl6, IgA/IgG and IgM. Focus score (FS), relative area of lymphocytic infiltrate, level of lymphoid organization and presence of a plasma cell shift were determined. In addition, number of lymphoepithelial lesions, germinal centers, follicular dendritic cell networks, B-cells and T-cells were analyzed.

Results: All histopathological parameters differed significantly between pSS and non-SS sicca patients in both labial and parotid salivary gland sections. Comparison of the two salivary gland types of non-SS sicca patients revealed more signs of inflammation in labial gland biopsies as shown by a significantly higher FS, CD3+ T-cells, CD20+ B-cells and relative area of CD45+ infiltrates compared to non-SS parotid salivary gland biopsies. Other histopathological parameters were comparable between the two types of salivary glands. In pSS patients, a higher FS and relative area of CD45+infiltrates was observed in labial gland biopsies compared to parotid gland biopsies. Nevertheless, relative and absolute CD20+ B-cell counts, GCs/mm2 and LELs/mm2 were higher in parotid gland parenchyma.

Conclusion: This study shows in labial salivary gland biopsies of non-SS sicca patients more signs of (unspecific) inflammation compared to parotid biopsies. In parotid gland biopsies signs of B-cell hyperactivity, such as number of CD20+B-cells, GCs/mm2 and LELs/mm2, are more pronounced, compared to labial gland biopsies. These histopathological differences should be taken into consideration in diagnosis and classification of Sjögren’s disease.

Supporting image 1

Figure 1. Relative area of CD45+infiltrates in salivary gland sections of non-SS sicca and primary Sjögren’s syndrome patients.

Supporting image 2

Table 1. Histopathological data of labial and parotid salivary gland biopsies in non-SS sicca patients and primary Sjögren’s syndrome patients.


Disclosures: U. Nakshbandi, None; M. van Ginkel, None; S. Liefers, None; H. Bootsma, Novartis, Bristol-Myers Squibb(BMS); F. Spijkervet, None; A. Vissink, None; B. van der Vegt, None; F. Kroese, None.

To cite this abstract in AMA style:

Nakshbandi U, van Ginkel M, Liefers S, Bootsma H, Spijkervet F, Vissink A, van der Vegt B, Kroese F. Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/labial-and-parotid-salivary-gland-histopathology-in-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/labial-and-parotid-salivary-gland-histopathology-in-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology